BridgeBio Pharma (2CL) Stock Forecast & Price Target
2CL Analyst Ratings
Strong Buy
17Buy1Hold0Sell
Based on 18 analysts giving stock ratings to BridgeBio Pharma in the past 3 months
2CL Stock 12 Month Forecast
Average Price Target
EUR 98.10▲(47.17% Upside)Based on 18 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is EUR 98.10 with a high forecast of EUR 139.68 and a low forecast of EUR 78.80. The average price target represents a 47.17% change from the last price of EUR 66.66.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 139.68
AverageEUR 98.10
LowEUR 78.80
Highest Price TargetHighestEUR 139.68Average Price TargetEUR 98.10Lowest Price TargetLowestEUR 78.80
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | Barclays | EUR 139.68 | buy | 109.54%Upside | Reiterated | 11/02/26 | ||
| Derek Archila | Wells Fargo | EUR 91.33 | buy | 37.01%Upside | Reiterated | 10/30/26 | ||
| Eric Joseph | Citi | EUR 81.48 | hold | 22.23%Upside | Reiterated | 10/30/26 | ||
| Joon Lee | UBS | EUR 82.38 | buy | 23.58%Upside | Reiterated | 10/30/26 | ||
| Biren Amin | Piper Sandler | EUR 107.45 | buy | 61.19%Upside | Reiterated | 10/30/26 | ||
| Luca Issi | RBC Capital | EUR 89.54 | buy | 34.32%Upside | Reiterated | 10/30/26 | ||
| Sean Laaman | Morgan Stanley | EUR 77.90→EUR 78.80 | buy | 18.20%Upside | Reiterated | 10/30/26 | ||
| Cory Kasimov | Evercore ISI | EUR 116.40 | buy | 74.62%Upside | Reiterated | 10/30/26 | ||
| Tyler Van Buren | TD Cowen | EUR 98.49→EUR 89.54 | buy | 34.32%Upside | Reiterated | 10/30/26 | ||
| Jason Zemansky | Bank of America Securities | ― | buy | ― | Reiterated | 10/30/26 | ||
| Joshua Schimmer | Cantor Fitzgerald | EUR 98.49 | buy | 47.76%Upside | Reiterated | 10/29/26 | ||
| Ram Selvaraju | H.C. Wainwright | EUR 107.45 | buy | 61.19%Upside | Reiterated | 10/15/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 10/06/26 | ||
| Whitney Ijem | Canaccord Genuity | EUR 94.91 | buy | 42.38%Upside | Reiterated | 10/06/26 | ||
| Andrew Tsai | Jefferies | EUR 98.49 | buy | 47.76%Upside | Reiterated | 08/31/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | 11/02/26 | EUR 139.68 | buy | 109.54%Upside | Reiterated | Barclays | ||
| Derek Archila | 10/30/26 | EUR 91.33 | buy | 37.01%Upside | Reiterated | Wells Fargo | ||
| Eric Joseph | 10/30/26 | EUR 81.48 | hold | 22.23%Upside | Reiterated | Citi | ||
| Joon Lee | 10/30/26 | EUR 82.38 | buy | 23.58%Upside | Reiterated | UBS | ||
| Biren Amin | 10/30/26 | EUR 107.45 | buy | 61.19%Upside | Reiterated | Piper Sandler | ||
| Luca Issi | 10/30/26 | EUR 89.54 | buy | 34.32%Upside | Reiterated | RBC Capital | ||
| Sean Laaman | 10/30/26 | EUR 77.90→EUR 78.80 | buy | 18.20%Upside | Reiterated | Morgan Stanley | ||
| Cory Kasimov | 10/30/26 | EUR 116.40 | buy | 74.62%Upside | Reiterated | Evercore ISI | ||
| Tyler Van Buren | 10/30/26 | EUR 98.49→EUR 89.54 | buy | 34.32%Upside | Reiterated | TD Cowen | ||
| Jason Zemansky | 10/30/26 | ― | buy | ― | Reiterated | Bank of America Securities | ||
| Joshua Schimmer | 10/29/26 | EUR 98.49 | buy | 47.76%Upside | Reiterated | Cantor Fitzgerald | ||
| Ram Selvaraju | 10/15/26 | EUR 107.45 | buy | 61.19%Upside | Reiterated | H.C. Wainwright | ||
| Myles Minter | 10/06/26 | ― | buy | ― | Reiterated | William Blair | ||
| Whitney Ijem | 10/06/26 | EUR 94.91 | buy | 42.38%Upside | Reiterated | Canaccord Genuity | ||
| Andrew Tsai | 08/31/26 | EUR 98.49 | buy | 47.76%Upside | Reiterated | Jefferies |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering BridgeBio Pharma
3 Months
Success Rate13/18 ratings generated profit
72%
Average Return
+13.63%
Copying Cory Kasimov's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +13.63% per trade.
1 Year
Success Rate22/24 ratings generated profit
92%
Average Return
+53.97%
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +53.97% per trade.
2 Years
Success Rate24/26 ratings generated profit
92%
Average Return
+104.37%
Copying Anupam Rama's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +104.37% per trade.
2CL Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 14 | 7 | 9 | 21 | 19 |
| Buy | 23 | 31 | 26 | 27 | 9 |
| Hold | 6 | 3 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 43 | 41 | 37 | 51 | 30 |
In the current month, 2CL has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2CL average Analyst price target in the past 3 months is 98.10.
2CL Financial Forecast
HighEUR 0.12
ConsensusEUR -0.53
LowEUR -0.89
2CL Earnings Forecast
Next quarter’s earnings estimate for 2CL is -EUR 0.53 with a range of -EUR 0.89 to EUR 0.12. The previous quarter’s EPS was -EUR 0.38. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 355M
ConsensusEUR 277M
LowEUR 250M
2CL Sales Forecast
Next quarter’s sales forecast for 2CL is EUR 277.03M with a range of EUR 249.82M to EUR 355.32M. The previous quarter’s sales results were EUR 316.23M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
2CL Stock Forecast FAQ
What is DE:2CL’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Pharma’s 12-month average price target is €98.10.
What is DE:2CL’s upside potential, based on the analysts’ average price target?
BridgeBio Pharma has 47.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BridgeBio Pharma a Buy, Sell or Hold?
BridgeBio Pharma has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
What is BridgeBio Pharma’s share price target?
The average share price target for BridgeBio Pharma is €98.10. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €139.68, and the lowest forecast is €78.80. The average share price target represents a 47.17% increase from the current price of €66.66.
What do analysts say about BridgeBio Pharma?
BridgeBio Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of BridgeBio Pharma?
To buy shares of DE:2CL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
